自然杀伤细胞亚群和自然细胞毒性受体在急性髓系白血病免疫治疗结局中的作用
Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
作者信息
Martner Anna, Rydström Anna, Riise Rebecca E, Aurelius Johan, Anderson Harald, Brune Mats, Foà Robin, Hellstrand Kristoffer, Thorén Fredrik B
机构信息
TIMM Laboratory; Sahlgrenska Cancer Center; University of Gothenburg ; Gothenburg, Sweden.
TIMM Laboratory; Sahlgrenska Cancer Center; University of Gothenburg; Gothenburg, Sweden; Department of Hematology; University of Gothenburg; Gothenburg, Sweden.
出版信息
Oncoimmunology. 2015 May 5;5(1):e1041701. doi: 10.1080/2162402X.2015.1041701. eCollection 2016.
In a phase IV trial, 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin 2 (IL-2) for 18 months to prevent leukemic relapse. During cycles, the treatment resulted in expansion of CD56(bright) (CD3(-)/16(-)/56(bright)) and CD16(+) (CD3(-)/16(+)/56(+)) natural killer (NK) cells in the blood along with increased NK cell expression of the natural cytotoxicity receptors (NCRs) NKp30 and NKp46. Multivariate analyses correcting for age and risk group demonstrated that high CD56(bright) NK cell counts and high expression of NKp30 or NKp46 on CD16(+) NK cells independently predicted leukemia-free survival (LFS) and overall survival (OS). Our results suggest that the dynamics of NK cell subsets and their NCR expression may determine the efficiency of relapse-preventive immunotherapy in AML.
在一项IV期试验中，84例年龄在18 - 79岁之间、处于首次完全缓解（CR）期的急性髓系白血病（AML）患者接受了为期18个月的组胺二盐酸盐（HDC）和低剂量人重组白细胞介素2（IL - 2）免疫治疗周期，以预防白血病复发。在治疗周期中，该治疗导致血液中CD56(bright)（CD3(-)/16(-)/56(bright)）和CD16(+)（CD3(-)/16(+)/56(+)）自然杀伤（NK）细胞扩增，同时自然细胞毒性受体（NCRs）NKp30和NKp46在NK细胞上的表达增加。校正年龄和风险组的多变量分析表明，高CD56(bright) NK细胞计数以及CD16(+) NK细胞上NKp30或NKp46的高表达可独立预测无白血病生存期（LFS）和总生存期（OS）。我们的结果表明，NK细胞亚群的动态变化及其NCR表达可能决定AML复发预防性免疫治疗的效果。
Zotero 插件